CTOs on the Move

Werewolf Therapeutics

www.werewolftx.com

 
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.werewolftx.com
  • 1030 Massachusetts Avenue Suite 210
    Cambridge, MA USA 02138
  • Phone: n/a

Executives

Name Title Contact Details
Chulani Karunatilake
 Chief Technology Officer Profile

Funding

Werewolf Therapeutics raised $56M on 11/20/2019

Similar Companies

ConjuGon Inc

ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Sciences

Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CMAC Consultancy

CMAC Consultancy is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.

Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.